Current State of Immunotherapy for Alzheimer’s Disease

CNS Spectrums

Volumn 13, Issue S16, 2008, Pages 39-41

  Relkin, Norman R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; IMMUNOGLOBULIN; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; RIVASTIGMINE; TACRINE; AN-1792; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ARTICLE; BRAIN EDEMA; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG TOLERABILITY; DRUG WITHDRAWAL; HORMONE SUBSTITUTION; HUMAN; HYPOTHESIS; IMMUNOTHERAPY; MENINGOENCEPHALITIS; NEUROTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN SYNTHESIS; UNSPECIFIED SIDE EFFECT; BRAIN; METHODOLOGY; PATHOLOGY; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; HUMANS; IMMUNOTHERAPY; SENILE PLAQUES;

EID: 56249086873     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900027061     Document Type: Article

References (10)

1. Zagorski, MG, Yang, J, Shao, H, Ma, K, Zeng, H, Hong, A. Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity. Methods Enzymol. 1999; 309: 189–204.
2. Hilbich, C, Kisters-Woike, B, Reed, J, Masters, CL, Beyreuther, K. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer’s disease. J Mol Biol. 1991; 218: 149–163.
3. Weksler, ME, Gouras, G, Relkin, NR, Szabo, P. The immune system, amyloid-beta peptide, and Alzheimer’s disease. Immunol Rev. 2005; 205: 244–256.
4. Zlokovic, BV. Clearing amyloid through the blood-brain barrier. J Neurochem. 2004; 89(4): 807–811.
5. Schenk, D, Barbour, R, Dunn, W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400(6740): 173–177.
6. Morgan, D, Diamond, DM, Gottschall, PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature. 2000; 408(6815): 982–985.
7. Nicoll, JA, Wilkinson, D, Holmes, C, Steart, P, Markham, H, Weller, RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003; 9(4): 448–452.
8. Lombardo, JA, Stern, EA, McLellan, ME, et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci. 2003; 23(34): 10879–10883.
9. Pfeifer, M, Boncristiano, S, Bondolfi, L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002; 298(5597):1379.
10. Relkin, N, Tsakanikas, DI, Adamiak, B, et al. A Double Blind, Placebo-Controlled, Phase II Clinical Trial of Intravenous Immunoglobulin (IVIG) for Treatment of Alzheimer’s Disease. Presented at: Annual Meeting of the American Academy of Neurology; April 12-19, 2008; Chicago, IL. Session S41.007